| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/11/2007 | US7267813 Inhalation particles incorporating a combination of two or more active ingredients |
| 09/11/2007 | CA2310536C Erythropoietin derivatives |
| 09/11/2007 | CA2309196C Novel camptothecin derivatives |
| 09/11/2007 | CA2115355C Novel tetrapeptide derivative |
| 09/07/2007 | WO2007101202A1 Cell-targeted ikb and methods for the use thereof |
| 09/07/2007 | WO2007100646A1 Multi-cyclic compounds and method of use |
| 09/07/2007 | WO2007100566A2 Use of dha and ara in the preparation of a composition for regulating gene expression |
| 09/07/2007 | WO2007100548A1 Use of manzamine compounds in anti-cancer therapeutic regimens |
| 09/07/2007 | WO2007100385A2 Macrocyclic depsipeptide antibody-drug conjugates and methods |
| 09/07/2007 | WO2007100304A1 Methods for cancer therapy and stem cell modulation |
| 09/07/2007 | WO2007100295A1 Novel dual action receptors antagonists (dara) at the ati and eta receptors |
| 09/07/2007 | WO2007100211A1 Sisp-1, a novel p53 target gene and use thereof |
| 09/07/2007 | WO2007100098A1 Multimer of extracellular domain of cell surface functional molecule |
| 09/07/2007 | WO2007100091A1 Composition for suppressing the expression of fucosyltransferase |
| 09/07/2007 | WO2007100066A1 17β HSD type 5 INHIBITOR |
| 09/07/2007 | WO2007099981A1 Galactose derivative, drug carrier and medicinal composition |
| 09/07/2007 | WO2007099869A1 Therapeutic and preventive agent for hcv |
| 09/07/2007 | WO2007099345A1 Medical use of bmp-2 and/ or bmp-4 |
| 09/07/2007 | WO2007099335A1 Quinoline derivatives for treating cancer |
| 09/07/2007 | WO2007099326A1 Quinoline derivatives |
| 09/07/2007 | WO2007099317A1 Quinazoline derivatives |
| 09/07/2007 | WO2007099304A1 Steroidal compounds as steroid sulphatase inhibitors |
| 09/07/2007 | WO2007099171A2 Bicyclo-pyrazoles active as kinase inhibitors |
| 09/07/2007 | WO2007099166A1 Pyrazolo-pyridine derivatives active as kinase inhibitors |
| 09/07/2007 | WO2007099117A1 Thiopyrophosphate organic compounds, method for preparing thereof and compositions containing them |
| 09/07/2007 | WO2007098835A1 Amino pyrymidine derivatives |
| 09/07/2007 | WO2007098719A1 Use of ck2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs |
| 09/07/2007 | WO2007098611A1 Compositions for treatment of cancer |
| 09/07/2007 | WO2007098588A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 09/07/2007 | WO2007098575A1 Cytotoxicity mediation of cells evidencing surface expression of cd44 |
| 09/07/2007 | WO2007098548A1 A molecule and chimeric molecules thereof |
| 09/07/2007 | WO2007098520A1 Process for the manufacture of a composition containing at least one xanthophyll |
| 09/07/2007 | WO2007084857A3 Methods and compositions for treating cell proliferative disorders |
| 09/07/2007 | WO2007082483B1 Medicament for treatment of tumor and the use thereof |
| 09/07/2007 | WO2007082482B1 Novel compound for treatment of tumor |
| 09/07/2007 | WO2007077028A3 Antibodies directed to her-3 and uses thereof |
| 09/07/2007 | WO2007060240A3 Method for demonstrating presence or absence of markers (eef1a1 or mark3 )associated with the presence and/or the chemosensitivity of tumors |
| 09/07/2007 | WO2007058991A3 Mutations and polymorphisms of c-abl |
| 09/07/2007 | WO2007047803A3 Use of prolactin in the prophylactic treatment of cancer |
| 09/07/2007 | WO2007039231A3 Method of producing a modified (poly)peptide |
| 09/07/2007 | WO2007023243A3 Cleavage of antifolate compounds |
| 09/07/2007 | WO2007011760A3 Inhibitors of mitotic kinesin |
| 09/07/2007 | WO2007009539A3 Use of inhibitors of histone deacetylases in combination with nsaid for the therapy of cancer and/or inflammatory diseases |
| 09/07/2007 | WO2006110476A3 Cytotoxic compounds and conjugates comprising duocarmycins with cleavable substrates |
| 09/07/2007 | CA2650113A1 Ankyrin-like motif-based peptides for the treatment of cancer |
| 09/07/2007 | CA2645123A1 Use of dha and ara in the preparation of a composition for regulating gene expression |
| 09/07/2007 | CA2644809A1 17 .beta. hsd type 5 inhibitor |
| 09/07/2007 | CA2644578A1 Novel dual action receptors antagonists (dara) at the ati and eta receptors |
| 09/07/2007 | CA2644566A1 Cancer treatments |
| 09/07/2007 | CA2643723A1 Cathepsin propeptide and uses thereof |
| 09/07/2007 | CA2643708A1 Cytotoxicity mediation of cells evidencing surface expression of cd44 |
| 09/07/2007 | CA2643100A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 09/07/2007 | CA2642973A1 Quinoline derivatives |
| 09/07/2007 | CA2642943A1 Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs |
| 09/07/2007 | CA2642813A1 Inhibitors of histone deacetylase |
| 09/07/2007 | CA2638797A1 Galactose derivative, drug carrier and medicinal composition |
| 09/07/2007 | CA2638734A1 Inhibitors of the unfolded protein response and methods for their use |
| 09/07/2007 | CA2636431A1 Steroidal compounds as steroid sulphatase inhibitors |
| 09/07/2007 | CA2633069A1 New 3'-, 7-substituted indirubins and their applications |
| 09/07/2007 | CA2617600A1 Attenuated reovirus |
| 09/06/2007 | US20070208167 Compounds and methods for modulating activation of NF-kappaB |
| 09/06/2007 | US20070208066 ER-beta-selective ligands |
| 09/06/2007 | US20070208049 e.g. 1-(2,6-Difluorobenzyl)-5-(3-Mehthoxyphenyl)-6-Methyl-3-[N-Methyl -N -(2-Pyridylethyl)Aminoethyl]Uracil; anticarcinoganic agent; prostate cancer, benign prostatic hypertrophy, breast cancer and endometriosis |
| 09/06/2007 | US20070208046 such as 4-benzyloxy-1-{4-[2-(dimethylamino)ethoxy]phenyl}-1H-pyridin-2-one, that as antagonists to melanin concentrating hormone receptors, used for treating cardiovascular, nervous system, metabolic, reproductive system, respiratory system and gatrointestinal disorders |
| 09/06/2007 | US20070208033 Amine compound and use thereof |
| 09/06/2007 | US20070208016 1-(3-tert-butyl-4-methoxy-5-morpholinophenyl)-2-(5,6-diethoxy-7-fluoro-1-imino-1,3-dihydroisoindol-2-yl)ethanone,; stabilizing the composition; not decompose even when placed under humidification conditions |
| 09/06/2007 | US20070208008 Substituted sulfonamides and ureas useful for inhibiting kinase activity |
| 09/06/2007 | US20070208007 Amine-Based Compound and Use Thereof |
| 09/06/2007 | US20070207967 Peptide Inhibitors of Matrix Metalloproteinase Activity |
| 09/06/2007 | US20070207943 Interleukins-21 and 22 |
| 09/06/2007 | US20070207198 Use Of N-Acety1-D-Glucosamine In The Manufacture Of Medicaments For Anti-Tumors And Anti-Metastasis |
| 09/06/2007 | US20070207163 Recombinant soluble Fc receptors |
| 09/06/2007 | US20070207153 Therapeutic Agents For Inner Ear Disorders Containing An Il-6 Antagonist As An Active Ingredient |
| 09/06/2007 | US20070207146 Therapeutic using a bispecific antibody |
| 09/06/2007 | US20070207143 Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 |
| 09/06/2007 | US20070207123 Amelioration of effects of cigarette smoke |
| 09/06/2007 | DE102006008880A1 Aminopyrimidinderivate Aminopyrimidine derivatives |
| 09/06/2007 | DE102005018641B4 Verwendung von Verbindungen zur Prophylaxe und / oder Behandlung von Tumoren Use of compounds for the prophylaxis and / or treatment of tumors |
| 09/05/2007 | EP1829967A1 Method of diagnosing malignant lymphoma and estimating the prognosis thereof |
| 09/05/2007 | EP1829963A1 Novel shuttle vector |
| 09/05/2007 | EP1829962A1 Method of preparing antibody by use of cell having its fucose transporter function inhibited |
| 09/05/2007 | EP1829961A1 Method of preparing antibody by use of cell having its fucose transporter function inhibited |
| 09/05/2007 | EP1829889A2 Kahalalide f and related compounds |
| 09/05/2007 | EP1829888A1 Anti-inflammatory compounds and uses thereof |
| 09/05/2007 | EP1829881A1 Combination of rapamycin and its tetrazole isomers and epimers, methods of making and using the same |
| 09/05/2007 | EP1829880A2 Derivatives of camptothecin for use in treating cancer |
| 09/05/2007 | EP1829551A1 Modified heat shock protein-antigenic peptide complex |
| 09/05/2007 | EP1829535A2 Tissue factor antagonists and methods of use thereof |
| 09/05/2007 | EP1829530A2 Stabilisation of active agents by formulation into nanoparticulate form |
| 09/05/2007 | EP1829529A1 Controlled release compositions of estradiol metabolites |
| 09/05/2007 | EP1828389A1 Sparc promoter mutations associated with drug resistance, and methods, oligonucleotides, cells and arrays associated therewith |
| 09/05/2007 | EP1828249A2 Biomarkers for pre-selection of patients for anti-igf1r therapy |
| 09/05/2007 | EP1828248A2 Compositions comprising anti-igf-1 receptor antibodies and methods for obtaining said antibodies |
| 09/05/2007 | EP1828209A2 Sulfonamido-macrocycles as tie2 inhibitors |
| 09/05/2007 | EP1828201A2 Macrocyclic quinazoline derivatives and their use as mtki |
| 09/05/2007 | EP1828186A1 Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| 09/05/2007 | EP1828185A2 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors |
| 09/05/2007 | EP1828184A1 [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases |
| 09/05/2007 | EP1828183A1 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors |
| 09/05/2007 | EP1828169A2 Urea inhibitors of map kinases |